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Abstract:	   Cognitive	   dysfunction,	   mood	   and	   anxiety	   disorders	   are	   three	   out	   of	   the	   five	   psychiatric	  syndroms	  included	  in	  Neuropsychiatric	  Lupus.	  These	  manifestations	  are	  among	  the	  most	  prevalent	  in	  SLE	  having	  an	   important	   impact	  on	  patients	  quality	  of	   life.	  However,	   the	  unknown	  etiology	  allied	  to	  the	   lack	   of	   clarity	   on	   the	   best	   diagnosis	   procedure,	  makes	   early	   diagnosis	   dificult.	   This	  manuscript	  reviews	  the	  recent	  literature	  on	  the	  screening	  intruments	  focused	  on	  identifying	  lupus	  patients	  with	  probable	  psychiatric	  manifestations.	  	  	  
Resumo:	   Disfunção	   cognitiva,	   distúrbios	   do	   humor	   e	   ansiedade	   são	   três	   das	   cinco	   síndromes	  
psiquiátricas	  incluídas	  na	  Lupus	  Neuropsiquiatrica.	  Estas	  manifestações	  estão	  entre	  as	  mais	  prevalentes	  
na	   lúpus	   e	   têm	   um	   impacto	   importante	   na	   qualidade	   de	   vida	   destes	   doentes.	   Apesar	   disto,	   o	  
deconhecimento	   etiológico	   aliado	   à	   falta	   de	   um	   processo	   diagnóstico	   ideal,	   fazem	   com	   que	   o	   seu	  
diagnóstico	   seja	   por	   vezes	   difícil.	  Neste	   trabalho	   é	   apresentada	  uma	   revisão	   da	   literatura	   recente	   dos	  
instrumentos	   de	   rastreio	   da	   idetificação	   de	   doentes	   com	   lúpus	   com	   prováveis	   manifestações	  
psiquiátricas.	  	  	  	  
Key-­words:	   Neuropsychiatric	   Lupus,	   Screening,	   Cognitive	   Dysfunction,	   Mood	   Disorders,	   Anxiety	  Disorders.	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INTRODUCTION	  
Systemic	   Lupus	   Erythematosus	   (SLE)	   is	   a	   chronic,	   inflammatory,	   autoimmune	   disease	  
characterized	   by	   its	  multi-­‐systemic	   involvement	   and	  multiple	   clinical	  manifestations.	   It	  
can	  involve	  the	  nervous	  system	  on	  its	  central	  or	  peripheral	  component.	  
In	   an	   effort	   to	   standardize	   nomenclature	   and	   diagnostic	   methodology,	   the	   American	  
College	   of	   Rheumatology	   Ad	   Hoc	   Committee	   on	   Neuropsychiatric	   Lupus,	   published	   in	  
1999,	   the	   case	  definitions	   and	  diagnostic	   recommendations	  on	  Neuropsychiatric	   Lupus	  
(NPSLE).	  Nineteen	  syndromes	  were	  included	  in	  NPSLE	  and	  for	  each	  were	  suggested	  not	  
only	   the	   diagnostic	   criteria	   and	   testing	   but	   also	   associations	   and	   exclusions1.	   The	  
publication	  was	  widely	  accepted	  and	  has	  been	  used	  ever	  since	  in	  the	  study	  of	  NPSLE	  in	  
adult	  and	  pediatric	  populations.	  	  
Recent	   studies	   report	   a	   prevalence	   of	   neuropsychiatric	   manifestations	   of	   27-­‐80%	   in	  
adults2-­‐8,	  and	  22-­‐95%	  in	  children9-­‐12.	  NPSLE	  can	  develop	  in	  any	  time	  during	  the	  course	  of	  
the	   disease	   but	   there	   are	   several	   studies	   reporting	   a	   tendency	   to	   occur	   early	   in	   its	  
course5,8.	  Furthermore,	  association	  between	  neuropsychiatric	  events	  and	  disease	  activity	  
has	  been	  reported	  in	  some	  studies13,	  14	  and	  denied	  in	  others15-­‐19.	  
Five	  out	  of	  19	  syndromes	  that	  included	  in	  NPSLE	  are	  psychiatric	  and	  were	  considered	  by	  
the	  ACR	  Ad	  Hoc	  Committee	  on	  NPSLE	  according	  to	  the	  DSM-­‐IV	  diagnostic	  criteria:	  mood	  
disorders,	   anxiety	   disorders,	   cognitive	   dysfunction,	   psychosis	   and	   acute	   confusional	  
state.	  	  
The	   importance	  of	   studying	  psychiatric	  phenomena	   in	   lupus	  disease	   lies	  not	  only	   in	   its	  
high	   prevalence	   reported20	   but	   mainly	   in	   what	   it	   represent	   clinically	   and	  
socioeconomically.	   Psychiatric	   manifestations	   have	   been	   associated	   with	   a	   decreased	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quality	   of	   life5,8,19,	   increased	   functional	   disability3,	   sleep	   disorders21,22,	   increased	  
unemployment	  rate23,34	  and	  health	  service	  utilization25,26.	  
There	  is	  still	  little	  consensus	  on	  the	  role	  of	  laboratory	  tests	  and	  imaging	  techniques	  in	  the	  
diagnosis	   of	   psychiatric	   syndromes	   and	   due	   to	   the	   lack	   of	   simple	   diagnosis	   process,	  
psychiatric	  syndromes	  are	  frequently	  undiagnosed.	  
This	  manuscript	  pretends	  to	  a	  be	  systematic	   review	  on	  the	  recent	   literature	   focused	   in	  
the	  study	  of	  screening	  tools	  for	  the	  identification	  of	  SLE	  patients	  with	  probable	  cognitive	  
dysfunction,	  mood	  disorders	  or	   anxiety	  disorders,	   the	   three	  most	  prevalent	  psychiatric	  
manifestations	  in	  lupus.	  
	  
METHODS	  
A	   Pubmed/Medline	   and	   Scopus	   search	   was	   conducted	   from	   January	   2002	   to	   January	  
2012	   using	   the	   following	   keywords:	   “neuropsychiatric	   lupus”	   or	   “systemic	   lupus	  
erythematosus”	   combined	  with	   “diagnosis”,	   “anxiety	  disorders”,	   “mood	  disorders”	  and	  
“cognitive	  dysfunction”.	  A	  follow-­‐up	  of	  the	  relevant	  bibliography	  in	  articles	  was	  also	  done	  
in	  order	  to	  identify	  additional	  relevant	  studies.	  
Abstracts	   of	   all	   identified	   studies	   were	   reviewed	   by	   two	   investigators.	   Every	   time	   an	  
abstract	  was	  considered	  as	  potentially	  relevant,	  by	  either	  or	  both	  investigators,	  the	  full-­‐
text	  was	   retrieved	   and	   reviewed	   for	   relevance	   by	   applying	   the	   exclusion	   and	   inclusion	  
criteria.	  
Review	  articles,	  case	  reports,	  studies	  in	  languages	  other	  than	  english	  or	  portuguese	  were	  
immediately	  excluded.	  Included	  were	  all	  the	  articles	  investigating	  a	  screening	  tool	  for	  the	  
diagnosis	   of	   psychiatric	   lupus.	   Studies	   that	   did	   not	   relate	  with	   diagnosis	   of	   psychiatric	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manifestations	  in	  the	  lupus	  setting	  or	  with	  its	  laboratory	  and/or	  imaging	  diagnosis	  were	  
also	  excluded.	  	  
	  
RESULTS	  
The	  described	  search	  identified	  446	  articles	  (Figure	  I),	  of	  which	  102	  were	  considered	  as	  
potentially	  relevant.	  Forty-­‐seven	  articles	  were	  excluded	  based	  on	  abstract	  analysis.	  The	  
remaining	   55	   studies	   were	   reviewed	   on	   its	   full	   text	   and	   the	   inclusion	   and	   exclusion	  
criteria	  were	  applied.	  Thirteen	  studies	  were	  included	  in	  this	  systematic	  review.	  
	  
COGNITIVE	  DYSFUNCTION	  
Difficulties	  in	  remembering,	  concentrating	  and	  performing	  cognitive-­‐dependent	  activities	  
are	  frequent	  complaints	  of	  SLE	  patients27,28.	  In	  fact	  Cognitive	  Dysfunction	  (CD)	  has	  been	  
reported	  as	  one	  of	   the	  most	   frequent	  neuropsychiatric	  manifestations	   in	   SLE,	  having	  a	  
prevalence	  in	  the	  adult	  population	  of	  5,4	  -­‐	  50	  %5,6,14,16,28-­‐33	  and	  in	  the	  pediatric	  population	  
of	  7,3	  -­‐	  79,8	  %5,6,14,19,29,30.	  
In	   adults	   CD	   increases	   the	   risk	   of	   physical	   injury,	   reduces	   patients	   ability	   to	   properly	  
adhere	   to	   treatment	   regimens	   and	   to	   function	   effectively	   in	   their	   home	   or	   work	  
environments17.	   In	   pediatric	   patients	   cognitive	   impairment	   may	   prevent	   the	   normal	  
development,	  with	  serious	  repercussions	  throughout	  life34.	  
A	  comprehensive	  battery	  of	  neuropsychological	  tests	  is	  the	  ideal	  method	  to	  evaluate	  the	  
presence	   and	   severity	   of	   cognitive	   dysfunction.	   However,	   in	   order	   to	   facilitate	   the	  
diagnosis	  process,	  the	  ACR	  Ad	  Hoc	  Committee	  on	  NPSLE	  proposes	  an	  one-­‐hour	  battery	  of	  
brief	  mental	  status	  examinations	  (short	  ACR-­‐SLE	  battery)1.	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The	  short	  ACR-­‐SLE	  battery	  has	  been	  validated	  and	  found	  reliable	  in	  spite	  of	  high	  practice-­‐
effect	  observed	   in	  some	  tests	  by	  a	  study	  that	  tested	  the	  correlation	  between	  the	  short	  
ACR-­‐SLE	   battery	   and	   a	   comprehensive	   neuropsychological	   battery35.	   Nevertheless	   the	  
short	   ACR-­‐SLE	   battery	   is	   not	   easily	   available,	   requires	   administration	   by	   specialized	  
professionals	  and	  is	  too	  expensive	  to	  be	  used	  in	  routine	  clinical	  consults15,27,28.	  	  
The	   ANAM	   is	   a,	   30	   to	   45	   minutes	   self-­‐administered,	   computerized	   battery	   of	  
neuropsychological	   tests,	   developed	   by	   U.S.	   military	   in	   order	   to	   assess	   the	   cognitive	  
repercussions	   of	   chemical	   agents,	   extreme	   environments	   and	   fatigue	   on	   cognitive	  
processing	  speed	  and	  efficiency27.	  
Holliday	  et	  al,	  in	  2003,	  was	  the	  first	  to	  suggest	  the	  use	  of	  ANAM	  as	  a	  screening	  tool	  in	  the	  
SLE	  context.	  This	  study	  administered	  both	  ANAM	  and	  a	  traditional	  test	  battery	  based	  on	  
ACR	  Ad	  Hoc	  Committee	  on	  NPSLE	  recommendations	   in	  a	  sample	  of	  67	  ethnically	  mixed	  
SLE	  patients	  enrolled	  in	  a	  large	  prospective	  cohort27.	  	  
The	   results	   showed	   that	   many	   ANAM	   measures	   correlated	   with	   the	   scores	   from	   the	  
traditional	  neuropsychological	   tests.	   It	  was	  also	   found	   that	  age	   is	  of	   little	   relevance	  on	  
the	   variance	   observed	   when	   accounted	   alone	   but,	   it	   acts	   as	   a	   powerful	   moderator	  
variable	  when	  is	  entered	  with	  ANAM	  variables	  into	  a	  linear	  regression	  model.	  This	  model	  
accounted	  for	  about	  61%	  of	  the	  variance	  in	  the	  average	  T-­‐score	  on	  the	  traditional	  tests27.	  
A	  Roebuck-­‐Spencer,	  2006	  publication,	  confirms	  the	  positive	  correlation	  between	  ANAM	  
and	   traditional	   neuropsychological	   testing.	   In	   this	   study	   the	   performances	   in	   the	   two	  
batteries	  are	  compared	  in	  a	  sample	  of	  60	  SLE	  patients	  participating	  in	  a	  large	  SLE	  cohort	  	  
on	  biomarkers	  of	  cognitive	  dysfunction.	  ANAM	  test	  battery	  demonstrated	  a	  sensibility	  of	  
76,2%	  and	  specificity	  of	  82,8%	  on	  the	  classification	  of	  individuals	  with	  probable	  cognitive	  
impairment	  versus	  no	  impairment	  in	  neuropsychological	  testing.	  ANAM	  remained	  a	  good	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screening	   tool	  when	  depression	  and	  sleepiness	  were	  present,	  measured	  with	  validated	  
self-­‐reported	   measures	   of	   sleepiness	   and	   depressed	   mood,	   suggesting	   that	   it	   is	   not	  
confounded	  by	  these.	  Furthermore,	  significant	  correlation	  between	  ANAM’s	  mood	  scale	  
and	  BDI-­‐II	  was	  found,	  supporting	  its	  use	  as	  a	  potential	  measure	  of	  emotional	  distress	  in	  
SLE	  patients36.	  
A	  2010	  study	  by	  Hanly	  et	  al,	  sought	  out	  to	  compare	  ANAM	  battery	  tests’	  performance	  in	  
a	   sample	   of	   29	   healthy	   controls,	   68	   Lupus	   (SLE),	   33	   Rheumatoid	   Arthritis	   (RA)	   and	   20	  
Multiple	  Sclerosis	  (MS)	  patients31.	  
The	   results	   showed	   a	   cognitive	   impairment	   of	   11-­‐50%	   in	   SLE	   patients	   (depending	   on	  
stringency	  of	  classification	  rules)	  when	  compared	  with	  locally	  recruited	  healthy	  controls.	  
However	   this	   frequency	   was	   comparable	   with	   the	   9-­‐61%	   calculated	   frequency	   in	   RA	  
patients	   and	   lower	   than	   that	   calculated	   for	   MS	   patients,	   20-­‐75%.	   The	   frequency	  
difference	  between	  SLE	  patients	  and	  patients	  with	  stable	  MS	  disease	  is	  expected	  but	  the	  
observed	  comparability	  of	  frequencies	  between	  SLE	  patients	  and	  patients	  with	  a	  disease	  
that	   does	   not	   affect	   primarily	   the	   CNS,	   as	   RA,	   raised	   questions	   about	   the	   presumed	  
etiology	   of	   deficits	   detected	   by	   ANAM.	   The	   authors	   suggested	   that	   the	   measures	  
evaluated	  by	  the	  ANAM	  battery	  do	  not	  distinguish	  between	  impaired	  mental	  processing	  
and	   speed	   sensoriomotor	   deficiencies	   and	   can	   instead	   represent	   CNS	  
immunosuppressive	   toxicity.	   Leading	   to	   the	   conclusion	   that	   ANAM	   can’t	   be	   used	   to	  
determine	   dysfunction	   on	   specific	   cognitive	   domains	   and	   it	   was	   not	   designed	   as	   a	  
substitute	  for	  formal	  neuropsychological	  assessment31.	  
In	   2007	   Brunner	   et	   al	   studied	   the	   statistical	   properties	   of	   the	   pediatric	   ANAM	   (ped-­‐
ANAM)	   in	   a	   childhood-­‐onset	   SLE	   sample.	   Ped-­‐ANAM	   and	   a	   battery	   of	   formal	  
neuropsychological	   tests	   (based	  on	  published	  data	   for	  SLE	  adults)	  were	  performed	   in	  a	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sample	   of	   27	   children	   with	   a	   median	   age	   of	   16,5	   years	   recruited	   from	   a	   pediatric	  
rheumatology	   clinic.	   A	   trend	   towards	   worse	   performance	   of	   participants	   with	   CD	  
compared	  to	  those	  without	  was	  observed	  in	  every	  performance	  parameter	  of	  the	  battery	  
but	  statistically	  significant	  differences	  between	  the	  two	  groups	  were	  only	  reached	  for	  3	  
out	   of	   the	   10	   ped-­‐ANAM	   tests.	   Furthermore,	   statistical	   significant	   correlations	   were	  
found	   between	   Ped-­‐ANAM	   tests	   and	   formal	   neuropsychological	   tests.	   Ped-­‐ANAM	  was	  
found	   as	   a	   promising	   tool	   to	   screen	   cognitive	   dysfunction	   in	   SLE	   children	   presenting	  
validity	  and	  promising	  sensitivity	  and	  specificity15.	  
The	   Cognitive	   Symptom	   Inventory	   (CSI)	   is	   a	   self-­‐administered	   paper	   questionnaire	  
consisting	   of	   21	   items	   focused	   in	   evaluating	   the	   subject’s	   ability	   to	   perform	   several	  
cognitive	  functions	  and	  activities	  of	  daily	  life.	  
In	  2002,	  Alarcón	  et	  al	  published	  a	  study	  which	  aimed	  determine	  the	  factor	  structure	  of	  
the	   CSI	   and	   the	   production	   of	   4	   factor	   scales	   and	   their	   correlation	   with	   3	   self-­‐report	  
measures	  of	  cognitive	  dysfunction	  and	  self-­‐report	  measures	  of	  fatigue,	  helplessness,	  self-­‐
efficacy,	  pain,	  social	  support	  and	  use	  of	  maladaptative	  coping	  skills.	  The	  sample,	  drawn	  
from	   a	   large	   prospective	   cohort	   (LUMINA),	   consisted	   in	   156	   ethnically	   mixed	   SLE	  
patients17.	  
The	   four	  main	   factors	   assessed	  by	   the	  CSI	  were	   found	   to	  be:	  Attention/Concentration,	  
Pattern/Activity	   Management,	   Intermediate	   Memory	   and	   Initiation	   of	   Executive	  
Functions.	   Despite	   the	   small	   shared	   amount	   of	   common	   variance	   between	   these	   four	  
factors,	  the	  correlation	  was	  not	  high	  enough	  that	  they	  duplicate	  one	  another17.	  	  
Modest	  statistically	  significant	  correlations	  were	  also	  found	  between	  CSI	  cognitive	  factor	  
scales	  and	  SLAM	  measure	  of	  Cortical	  Dysfunction,	  SF-­‐36	  	  measure	  of	  Mental	  Functioning,	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SDI	  measure	  of	  Cognitive	  Impairment,	  measures	  of	  fatigue,	  psychological	  distress,	  social	  
support,	  maladpative	  coping	  skills,	  self-­‐efficacy	  and	  pain17.	  	  
CSI	   patients’	   responses	   were	   found	   not	   to	   be	   confounded	   by	   social-­‐demographic	   or	  
clinical	  variables.	  The	  questionnaire	  was	  completed	  in	  an	  average	  time	  of	  10	  minutes	  and	  
with	  minimal	  paraprofessional	  help	   regardless	  of	  ethnical	  backgrounds	  or	  administered	  
language17.	  
The	   Montereal	   Cognitive	   Assessment	   (MoCA)	   is	   a	   validated,	   one-­‐page,	   physician-­‐
administred	  questionnaire	  used	  on	  the	  identification	  of	  mild	  cognitive	  dysfunction	  in	  the	  
elderly32.	  	  
Published	   in	   2011	   by	   Adhikari	   et	   al	   there	   is	   a	   study	   that	   aims	   to	   evaluate	  MoCA	   as	   a	  
screening	   tool	   for	  detection	  of	   cognitive	  dysfunction	   in	  SLE	  patients.	   In	  a	   sample	  of	  44	  
SLE	  patients	  recruited	  in	  the	  Cincinnati	  area	  (USA)	  were	  applied	  both	  the	  MoCA	  and,	  as	  
gold	  standard,	  the	  ANAM35.	  Results	  demonstrate	  that	  to	  a	  standard	  cutoff	  score	  of	  26	  the	  
sensitivity	  of	  MoCA	  was	  83%.	  The	  specificity	  was	  73%	  with	  a	  positive	  predictive	  valued	  of	  
50%	  and	   a	  negative	  predictive	   value	  of	   92%.	   These	   results	   suggest	   that	  MoCA	  has	   the	  
potential	  to	  be	  used	  as	  a	  screening	  tool	  for	  the	  detection	  of	  SLE	  with	  probable	  cognitive	  
dysfunction32.	  
In	   2008,	   Kozora	   et	   al	   publishes	   a	   study	   aimed	   to	   examine	   the	   screening	   utility	   of	   the	  
standardized	   neurologic	   evaluations	   in	   the	   identification	   of	   SLE	   patients	  with	   probable	  
cognitive	  dysfunction.	  All	   the	  participants	   in	   the	  study	  were	  already	  enrolled	   in	  a	   large	  
prospective	   cohort	   of	   cognitive	   functioning	   and	   neuroimaging.	   The	   participants	   were	  
selected	  based	  on	  the	  examination	  of	  their	  clinical	  history	  and	  on	  physician	  interview	  in	  
order	   to	   identify	   the	  ones	  with	  history	  of	  neuropsychiatric	  diseases	  or	  depression.	  The	  
Scripps	  Neurologic	  Rating	  Scale	  (NRS)	  and	  the	  short	  ACR-­‐SLE	  battery	  were	  administrated	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to	   all	   the	   participants	   (SLE=67,	   Controls=29)37.	   The	   NRS	   is	   a	   22	   item	   neurologic	   exam	  
developed	  for	  the	  clinical	  evaluation	  of	  patients	  with	  multiple	  sclerosis.	  
The	  prevalence	  of	  cognitive	  dysfunction	  in	  the	  sample	  was	  20,9%.	  The	  non-­‐NPSLE	  group	  
had	  worse	   outcomes	   on	   NRS	   global	   score	   than	   the	   control	   group	   (p<0,001).	   However	  
after	  analysis	  of	  the	  NRS	  parameters,	  the	  one	  responsible	  for	  the	  statistically	  significant	  
difference	  was	   “mentation	  and	  mood”.	  Nevertheless	   two	  patients	  were	  excluded	  after	  
the	  initial	  screening	  process	  during	  the	  administration	  of	  the	  neurologic	  examination	  by	  
the	  neurologist	  suggesting	  that	  the	  NRS	  can	  assure	  that	  overt	  neurologic	  dysfunction	   is	  
not	  present	  and	  assist	  in	  identifying	  non-­‐NPSLE	  patients37.	  	  
Julian	  et	  al	  publishes,	  in	  2011,	  a	  study	  aimed	  at	  the	  evaluation	  of	  the	  utility	  of	  telephone	  
screening	   and	   self-­‐report	   assessments	   of	   cognitive	   complaints	   in	   detecting	   cognitive	  
impairment	  in	  individuals	  with	  SLE	  and	  RA28.	  
Two	  screening	  measures	  were	  evaluated:	  a	  12-­‐15	  minutes	  telephone	  interview	  based	  on	  
three	   neuropsychological	   tests	   (see	   article	   for	   details)	   and	   the	   Perceived	   Deficits	  
Questionnaire	   (PDQ),	   a	   five-­‐question,	   self-­‐administered	   questionnaire.	   A	   validated	  
neuropsychological	   battery	   based	   on	   the	   short	   ACR-­‐SLE	   battery	   was	   used	   as	   “gold	  
standard”.	  
The	  sample	  of	  138	  SLE	  patients	  and	  84	  RA	  patients	  was	  drawn	  from	  two	  large	  cohorts	  of	  
SLE	  and	  RA	  patients,	   respectively.	  The	  cognitive	  dysfunction	  rates	  were	  27%	  to	  the	  SLE	  
group.	   The	   telephone	   screening	   had	   77%	   sensitivity,	   65%	   specificity,	   94%	   negative	  
predictive	   value,	   43%	  positive	   predictive	   value	   and	   67%	  of	   the	   patients	  were	   correctly	  
classified	   in	   the	   SLE	   group.	   While	   the	   PDQ	   had	   64%	   sensitivity,	   65%	   specificity,	   83%	  
negative	   predictive	   value,	   38%	  positive	   predictive	   value	   and	   64%	  of	   the	   patients	  were	  
correctly	  classified	  in	  the	  SLE	  group.	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Contrary	   to	   telephone	   screening	  measure,	   the	   PDQ	  was	   not	   a	   significant	   predictor	   of	  
cognitive	  impairment	  when	  adjusted	  for	  social-­‐demographic	  data	  and	  depression28.	  	  
	  
MOOD	  AND	  ANXIETY	  DISORDERS	  
The	   reported	   prevalence	   of	   mood	   and	   anxiety	   disorders	   in	   recent	   studies	   ranges	  
between	  12,4-­‐60%5,14,28,38-­‐41	  	  and	  6,4-­‐46,5%5,29,39,41,	  respectively.	  
The	  ACR	  Ad	  Hoc	  Committee	  on	  NPSLE	  recommends	  the	  use	  of	  standardized	  instruments	  
like	   the	  Center	   for	  Epidemiological	   Studies	   -­‐	  Depression	  Scale	   (CES-­‐D)	  and	   the	  Hospital	  
Anxiety	  and	  Depression	  Scale	  (HADS)	  for	  the	  diagnosis	  of	  mood	  and	  anxiety	  disorders1.	  
Several	  associations	  have	  been	  sought	  out	  by	  different	  studies	  in	  order	  to	  understand	  the	  
pathophysiology	  of	  these	  disorders.	  	  
The	  association	  between	  short	  disease	  duration	  and	  anxiety	  disorders	  was	  described	  in	  a	  
2011	  study	  by	  Hawro	  et	  al,	  raising	  the	  hypothesis	  that	  anxiety	  was	  a	  consequence	  of	  the	  
inadequate	   information	   about	   the	   disease	   suggesting	   that	   at	   least	   part	   of	   the	   anxious	  
disorders	  encountered	  in	  NPSLE	  have	  an	  adaptive	  background33.	  
Kozora	   et	   al	   in	   2007	   compared	   the	   performances	   of	   depressed	   SLE	   patients	   (n=13),	  
depressive	   non-­‐SLE	   patients	   (n=10)	   and	   healthy	   controls	   (n=25)	   in	   the	   short	   ACR-­‐SLE	  
battery	   and	   a	   comprehensive	  neuropsychological	   battery.	   The	   results	   of	   this	   study	  not	  
only	  confirmed	  the	  association	  between	  depression	  and	  cognitive	  dysfunction42	  but	  also	  
validated	   the	   short	   ACR-­‐SLE	   battery	   for	   the	   diagnosis	   of	   cognitive	   dysfunction	   in	  
depressed	  SLE	  patients43.	  
In	  a	  survey	  study	  published	  by	  Iverson	  et	  al	  in	  2002,	  two	  screening	  depression	  measures	  
were	   compared,	   Beck	   Depression	   Inventory-­‐Second	   Edition	   (BDI-­‐II)	   and	   the	   British	  
Columbia	  Major	  Depression	  Inventory	  (BCMDI),	  both	  instruments	  constructed	  according	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to	   the	   diagnostic	   criteria	   of	   DSM-­‐IV	   for	   depression.	   The	   sample	   consisted	   of	   103	   self-­‐
reported	  lupus	  patients	  (no	  attempt	  was	  made	  to	  confirm	  the	  diagnosis)	  and	  136	  healthy	  
controls.	   The	   self-­‐reported	   SLE	   group	   had	   higher	   rates	   of	   depression	   and	   vegetative	  
symptoms	   (fatigue,	   difficulty	   falling	   asleep,	   sadness,	   etc.)	   than	   the	   control	   group.	   The	  
results	  point	  to	  a	  possible	  over-­‐estimate	  diagnosis	  of	  depression	  in	  this	  study	  of	  103	  SLE	  
patients,	  as	  measured	  by	  the	  BDI-­‐II,	  a	  test	  that	  is	  considered	  valid	  and	  reliable	  screening	  
of	  depression.	  Fifteen	  percent	  of	  the	  patients	  identified	  as	  depressed	  on	  the	  BDI-­‐II	  scored	  
in	   the	   normal	   range	   on	   the	   BCMDI,	   and	   46%	   scored	   in	   the	   possibly	   depressed	   range.	  
Therefore,	  it	  is	  possible	  that	  the	  BDI-­‐II	  over-­‐identified	  depression	  in	  this	  sample22.	  
In	  a	  2011	  study	  by	  Julian	  et	  al,	  the	  Center	  for	  Epidemiological	  Studies	  -­‐	  Depression	  Scale	  
(CES-­‐D)	   is	   compared	   with	   the	   Mini-­‐International	   Neuropsychiatric	   Interview	   (MINI),	   a	  
validated	  diagnostic	  method	  based	  on	   structured	   clinical	   interview,	   in	   a	   sample	  of	   150	  
SLE	  patients	  drawn	  from	  a	  prospective	  cohort	  of	  957	  lupus	  patients.	  In	  this	  sample	  26%	  
of	   the	   patients	  were	   diagnosed	  with	   a	  mood	   disorder	   and	   17%	  with	  major	   depressive	  
disorder	   measured	   by	   the	   MINI.	   The	   results	   showed	   a	   92%	   of	   corrected	   classified	  
patients	  with	  major	  depressive	  disorder	  and	  a	  87%	  sensibility	  and	  specificity	  in	  detection	  
of	  any	  mood	  disorder	  with	  the	  CES-­‐D40.	  
Hyphantis	  et	  al,	  2011,	  studies	  the	  psychometric	  characteristics	  of	  the	  greek	  version	  of	  the	  
Patient	   Health	   Questionnaire-­‐9	   (PHQ-­‐9)	   in	   a	   diverse	   rheumatologic	   sample	   of	   558	  
patients	   (62	   lupus	   patients).	   The	   PHQ-­‐9	   is	   a,	   9	   question,	   self-­‐administered,	   simple,	  
questionnaire	  used	  on	  the	  screening	  and	  severity	  assessment	  of	  depression.	  The	  results	  
showed	  25,4%	  prevalence	  of	  Major	  Depressive	  Disorder,	  measured	  by	  MINI,	  and	  a	  81,2%	  
and	  86,8%,	  sensitivity	  and	  specificity,	  respectively,	  of	  the	  greek	  version	  PHQ-­‐944.	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PILOT	  SCREENING	  TOOL	  
Mosca	   et	   al	   published,	   in	   2011,	   a	   study	   aimed	   to	   create	   a	   questionnaire,	   to	   be	  
administered	  by	  physicians,	  that	  could	  be	  used	  as	  a	  screening	  tool	  for	  the	  identification	  
of	  neuropsychiatric	  manifestations	  in	  SLE	  patients	  with	  no	  obvious	  CNS	  involvement,	  for	  
further	  evaluation45.	  
Starting	  from	  group	  of	  112	  questions	  drawn	  from	  41	  questionnaires	  aimed	  at	  assessing	  
neuropsychiatric	  manifestations	  similar	   to	   those	  prevalent	   in	  NPSLE,	  a	  panel	  of	  experts	  
and	   statistic	   analysis	   created	   a	   draft	   questionnaire	   with	   62	   items.	   This	   draft	  
questionnaire	  was	   then	   tested	   in	   139	   SLE	   patients	   from	   11	   european	   centers	   and	   the	  
results	   were	   compared	   with	   clinical	   diagnosis	   made	   by	   a	   specialist.	   After	   additional	  
statistical	   analysis,	   the	   final	   questionnaire	   consisted	   of	   27	   items,	   15	   referring	   to	   the	  
central	  nervous	  system	  symptoms	  and	  12	  to	  psychiatric	  ones.	  
For	  a	  cutoff	  value	  of	  17	  the	  questionnaire	  had	  a	  sensitivity	  and	  specificity	  of	  93%	  and	  25%	  
respectively.	  It	  was	  found	  that	  the	  association	  of	  non-­‐specific	  symptoms	  (e.g.	  subjective	  
complain	   of	   cognitive	   dysfunction	   or	   headache)	   may	   determine	   a	   higher	   score	   than	  
serious	  manifestations	  such	  as	  seizures	  alone.	  All	  the	  initial	  included	  items	  aimed	  at	  the	  
assessment	   of	   peripheral	   nervous	   system	   symptoms	   were	   excluded	   based	   on	   the	  
methodology	   used.	   Despite	   the	   intent	   to	   be	   administered	   by	   a	   physician	   the	   authors	  
considered	  the	  questionnaire	  to	  be	  simple	  enough	  to	  be	  filled	  by	  the	  patient	  himself45.	  
	  
DISCUSSION	  
One	  of	  the	  most	  controversial	  topics	  in	  the	  study	  of	  the	  psychiatric	  manifestations	  is	  their	  
etiology.	   In	   fact,	  despite	   the	  high	  prevalences	   reported	   its	   still	  not	  known	   if	   they	  are	  a	  
direct	   consequence	  of	   the	   autoimmune	  disease	  or	   secondary	   to	   it.	   Several	   factors	   can	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explain	   the	   secondary	   nature	   of	   these	   disorders	   like	   the	   stress	   of	   having	   a	   chronic	  
disease,	  the	  lack	  of	  social	  support	  or	  the	  use	  of	  immunosuppresive	  therapy39.	  
Psychiatric	  syndromes	  are	  rarely	  diagnosed	  early	  in	  their	  course	  due	  to	  their	  initially	  faint	  
clinical	  manifestations	  and	   lack	  of	   accepted,	   valid	  and	  accessible	  methods	  of	  detection	  
which	  leads	  to	  under-­‐diagnosis	  and	  under-­‐treatment	  of	  these	  conditions.	  Thus,	  a	  simple,	  
sensitive	   screening	   test	   would	   serve	   to	   improve	   quality	   of	   management	   of	   lupus	  
patients32.	   On	   the	   other	   hand,	   randomized	   clinical	   trials	   are	   necessary	   in	   SLE	   to	   fully	  
understand	  the	  benefit-­‐harm	  tradeoffs	  for	  screening	  these	  psychiatric	  manifestations40.	  
Some	  instruments	  with	  the	  intend	  of	  screening	  cognitive	  dysfunction	  in	  SLE	  patients	  have	  
been	   recently	   analyzed.	   However	   a	   lot	   more	   research	   needs	   to	   be	   done	   in	   order	   to	  
validate	  them.	  With	  the	  exception	  of	  ANAM,	  all	   the	   instruments	  proposed	  as	  screening	  
tests	  across	  the	  literature	  were	  studied	  only	  once.	  	  
The	   ANAM	   presents	   as	   the	   most	   analyzed	   of	   the	   screening	   tools,	   presenting	   good	  
sensitivity	   and	   specificity	   (76,2%	   and	   82,4%,	   respectively)	   on	   the	   distinction	   of	   SLE	  
patients	   with	   cognitive	   dysfunction	   in	   formal	   neuropsychological	   testing	   from	   those	  
without.	  	   	  ANAM	  presents	  as	  a	  instrument	  with	  less	  sensitivity	  to	  confounding	  variables	  
such	  as,	  education,	  English	  proficiency	  and	  possible	  ethnic	  differences	  compared	  to	  the	  
formal	   neuropsychological	   testing27.	   Its	   accessibility,	   self-­‐administration,	   low	   practice-­‐
effects,	   reduced	   cost	   and	   validity	   in	   depressed	   lupus	   patients27,36	   makes	   of	   ANAM	   a	  
promising	   screening.	   The	   finding	   that	   it	   may	   be	   confounded	   by	   immunosuppressive	  
toxicity	   and/or	   sensoriomotor	   deficits31	   may	   not	   be	   as	   relevant	   clinically	   as	   it	   is	  
etiologically	  since	  regardless	  of	  cause	  attribution,	  cognitive	  dysfunction	  is	  a	  co-­‐morbidity	  
that	  needs	  to	  be	  addressed	  when	  diagnosed.	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Preliminary	   results	   determined	   that	   Cognitive	   Symptom	   Inventory	   (CSI),	   a	   10	   minutes	  
self-­‐administered	  paper	  test,	  has	  the	  potential	  to	  be	  used	  as	  a	  screening	  instrument	  on	  
the	   identification	  of	  SLE	  patients	  with	  probable	  cognitive	  dysfunction.	  Revision	  of	  some	  
of	   the	   items’	   content,	   expansion	   of	   the	   questionnaire	   so	   it	   covers	   other	   cognitive	  
domains,	  study	  of	  its	  psychometric	  characteristics	  and	  testing	  it	  in	  different	  samples	  are	  
some	  of	  the	  subjects	  that	  need	  to	  be	  addressed	  in	  further	  studies	  in	  order	  to	  validate	  the	  
CSI	   as	   a	   screening	   tool17.	   Contrary	   to	   CSI,	   the	   Perceived	   Deficits	   Questionnaire,	   a	   5	  
question	  self-­‐administered	  questionnaire	  was	  found	  to	  be	  a	  weak	  predictor	  of	  cognitive	  
impairment	  since	  it	  was	  confounded	  by	  social-­‐demographic	  data	  and	  depression28.	  
The	  Montereal	   Cognitive	   Assessment	   (MoCA),	   a	   physician	   administered	   questionnaire,	  
presented	  a	  83%	  sensitivity	  and	  73%	  specificity.	  However	  the	  “gold	  standard”	  used	  was	  
not	  formal	  neuropsychological	  testing	  but	  ANAM,	  which	  represents	  a	  vulnerability	  of	  the	  
study32.	  
In	  the	  Kozora	  et	  al	  study	  on	  the	  utility	  as	  a	  screening	  tool	  of	  the	  Scripps	  Neurologic	  Rating	  
Scale16	   the	   results	   were	   not	   too	   impressive	   since	   despite	   the	   significant	   difference	  
between	   SLE	   and	   control	   groups	   in	   identifying	   cognitive	   dysfunction,	   “mentation	   and	  
mood”	   was	   the	   parameter	   responsible	   for	   the	   statistically	   significant	   difference.	  
Furthermore,	  one	  aspect	  that	  was	  not	  referred	  in	  the	  study	  was	  how	  long	  did	  it	  take	  to	  
administer	  the	  neurologic	  exam,	  essential	  to	  determine	  the	  true	  time-­‐cost	  efficiency	  of	  it.	  
Another	  promising	  screening	  instrument	  is	  the	  Telephone	  Screening	  studied	  by	  Julian	  et	  
al,	  the	  43%	  positive	  predictive	  value	  	  and	  93%	  negative	  predictive	  value	  presented	  by	  this	  
tool,	   is	   an	   advantage	   in	   that	   permits	   to	   exclude	   with	   greater	   confidence	   individuals	  
without	  cognitive	  impairment28.	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It	  is	  somehow	  surprising	  that	  despite	  the	  high	  frequencies	  reported	  of	  mood	  and	  anxiety	  
disorders	   among	   lupus	   patients,	   and	   the	   number	   of	   measures	   available	   aiming	   the	  
screening	   of	   these	   disturbances,	   only	   two	   studies	   were	   found	   comparing	   the	  
performances	   of	   these	   tests	   in	   the	   lupus	   context.	   In	   fact,	   only	   in	   2011	   the	   Center	   for	  
Epidemiological	  Studies	  Depression	  Scale	  (CES-­‐D),	  recommended	  in	  1999	  by	  the	  ACR	  Ad	  
Hoc	  Committee	   on	  NPSLE	   as	   a	   screening	   tool	   to	   identify	   patients	  with	   probable	  mood	  
disorders,	  was	  tested,	  presenting	  a	  87%	  sensitivity	  and	  specificity	  in	  detecting	  any	  mood	  
disorder	  when	  compared	  with	  MINI40.	  
Studies	   like	   the	   one	   published	   by	   Hyphantis	   et	   al,	   that	   validated	   the	   greek	   version	   of	  
PHQ-­‐9	   in	   a	   large	   and	   diverse	   rheumatologic	   sample44,	   are	   very	   important	   since	  
questionnaires	  when	   translated	  need	   to	  be	  validated	  again	   in	  order	   to	  guarantee	   their	  
quality.	  
Pediatric	   Neuropsychiatric	   Lupus	   (Ped-­‐NPSLE)	   is	   even	   less	   understood	   than	   the	   adult	  
form	  due	  to	  the	  lack	  of	  studies	  published.	  The	  definition	  cases	  and	  diagnostic	  criteria	  and	  
testing	  recommended	  by	  the	  ACR	  Ad	  Hoc	  Committee	  on	  NPSLE	  are	  being	   inadequately	  
used	  in	  children.	  Williams	  et	  al	  demonstrated	  that	  depending	  on	  the	  methodology	  used	  
to	   classify	   cognitive	   impairment	   in	   children,	   the	   prevalence	   of	   cognitive	   dysfunction	  
ranged	  from	  7,3%	  to	  63,4%	  in	  the	  same	  sample.	  More	  than	  that	  no	  significant	  differences	  
were	  encountered	   in	   tested	  domain	   scores	  as	  well	   as	   cognitive	  dysfunction	  prevalence	  
estimates	  between	  lupus	  children	  and	  controls19.	  Another	  difficulty	  in	  studying	  pediatric	  
lupus	   is	   the	   small	   sample	   available,	   one	   of	   the	   main	   limitations	   of	   the	   Brunner	   et	   al	  
study15,	  that	  examined	  the	  usefulness	  of	  the	  pediatric	  version	  of	  ANAM	  in	  small	  sample	  
of	  27	  lupus	  children.	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Mosca	   et	   al	   approached	   screening	   testing	   in	   a	   holistic	   way,	   creating	   a	   physician-­‐
adminestered	   simple	   questionnaire	   to	   screen	   neuropsychiatric	   events.	   The	   main	  
limitation	   of	   the	   study	   is	   the	   lack	   of	   items	   that	   assess	   the	   peripheral	   nervous	   system,	  
justified	   by	   the	   authors	   as	   a	   result	   of	   the	   low	   prevalence	   of	   these	   phenomena	   in	   the	  
lupus	   context.	   Despite	   the	   low	   specificity	   demonstrated	   (25%)	   this	   is	   a	   revolutionary	  
study	  that	  demonstrated	  promising	  preliminary	  results45.	  
There	   is	   still	   a	   long	   way	   to	   go	   regarding	   Neuropsychiatric	   Lupus.	   Sample	   selection,	  
classification	   of	   impairment	   and	   attribution	   of	   cause	   are	   parameters	   that	   need	   to	   be	  
defined	  and	  standardized	  in	  order	  to	  compare	  studies	  and	  draw	  conclusions.	  	  
The	  screening	  of	  psychiatric	  manifestations	  needs	  to	  be	  evaluated	  through	  randomized	  
clinical	  trials	  in	  its	  true	  utility	  since	  the	  impact	  of	  early	  intervention	  on	  these	  phenomena	  
is	  still	  unknown.	  
The	   translation	   and	   validation	   of	   screening	   tools	   in	   portuguese	   might	   facilitate	   and	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n o r m a s d e p u b l i c a ç ã o
Os ma nus cri tos de vem ser acom pa nha dos de de cla ra -
ção de ori gi na li da de e de ce dên cia dos di rei tos de pro prie -
da de do ar ti go, as si na da por to dos os au to res, con for me
mi nu ta pu bli ca da em ane xo.
O tex to deve ser en vi a do em for ma to di gi tal (e-mail),
a dois es pa ços, com le tra ta ma nho12 e com mar gens não
in fe rio res a 2,5 cm, em Word para Win dows. To das as pá -
gi nas de vem ser nu me ra das. 
As ima gens de vem ser for ne ci das in de pen den te men -
te do tex to em for ma to JPEG ou TIFF.
Os tex tos de vem ser or ga ni za dos da se guin te for ma:
Pá gi na 1
a) Tí tu lo em por tu guês e in glês 
b) Nome dos au to res e res pec ti va afi li a ção  
c) Ser vi ço(s) ou or ga nis mo(s) onde o tra ba lho foi exe -
cu ta do 
d) Sub sí dio(s) ou bol sa(s) que con tri bu í ram para a rea -
li za ção do tra ba lho 
e) Mo ra da e e-mail do au tor res pon sá vel pela cor res -
pon dên cia re la ti va ao ma nus cri to 
f) Tí tu lo bre ve para ro da pé 
Pá gi na 2
a) Tí tu lo (sem au to res)
b) Re su mo em por tu guês e in glês, que para os ar ti gos
ori gi nais deve ser es tru tu ra do da se guin te for ma: Ob jec -
ti vos, Ma te ri al e Mé to dos, Re sul ta dos, Con clu sões. O re -
su mo dos ar ti gos ori gi nais não deve ex ce der as 350 pa la -
vras e o dos ca sos clí ni cos as 180 pa la vras.
c) Pa la vras-cha ve em por tu guês e em in glês (Key -
words)
Um má xi mo de 5 pa la vras-cha ve, uti li zan do a ter mi -
no lo gia que cons ta na lis ta do In dex Me di cus: «Me di cal
Sub ject He a dings» (MeSH), deve se guir-se ao re su mo. 
Pá gi na 3 e se guin tes
Ar ti gos ori gi nais: O tex to deve ser apre sen ta do com os
se guin tes sub tí tu los: In tro du ção (in clu in do Ob jec ti vos),
Ma te ri al e Mé to dos, Re sul ta dos, Dis cus são, Conclusões,
Agra de ci men tos (se apli cá vel), Re fe rên cias.
Os ar ti gos ori gi nais não de ve rão ex ce der as 4.000 pa -
la vras, com um to tal de 6 fi gu ras/ta be las e 60 re fe rên cias.
Caso clí ni co: os sub tí tu los se rão, In tro du ção, Caso clí -
ni co, Dis cus são, Re fe rên cias.
O caso clí ni co não deve ex ce der as 2.000 pa la vras e 25
re fe rên cias. Deve ser acom pa nha do de fi gu ras ilus tra ti -
vas. O nú me ro de ta be las/fi gu ras não deve ser su pe rior
a 6.
A par tir da se gun da pá gi na, in clu si ve, to das as pá gi nas
de vem ter em ro da pé o tí tu lo bre ve in di ca do na pá gi na 1.
Re fe rên cias: As re fe rên cias bi bli o grá fi cas de vem ser
clas si fi ca das e nu me ra das por or dem de en tra da no tex -
to, em su pers cript e não en tre pa rên te sis. As abre vi a tu ras
usa das na no me a ção das re vis tas de vem ser as uti li za das
pelo In dex Me di cus.
Nas re fe rên cias com 6 ou me nos au to res to dos de vem
ser no mea dos. Nas re fe rên cias com 7 ou mais au to res de -
vem ser no mea dos os 3 pri mei ros se gui dos de et al.
No tas: Os nú me ros da pá gi na ini ci al e fi nal de vem ser
to tal men te apre sen ta dos (565-569 e não 565-9)
A Acta Reu ma to ló gi ca Por tu gue sa pu bli ca ar ti gos ori -
gi nais so bre to dos os te mas da Reu ma to lo gia ou com ela
re la ci o na dos. São tam bém pu bli ca dos ar ti gos de re vi são,
ca sos clí ni cos, ima gens, car tas ao edi tor e ou tros que se
in cluam na es tru tu ra edi to ri al da re vis ta (re co men da ções,
ar ti gos so bre prá ti ca clí ni ca reu ma to ló gi ca, no tí cias de
re u ni ões de so ci e da des ci en tí fi cas, por ex.).
A Acta Reu ma to ló gi ca Por tu gue sa sub scre ve os re qui -
si tos para apre sen ta ção de ar ti gos a re vis tas bi o mé di cas
ela bo ra das pela Co mis são In ter na cio nal de Edi to res de
Re vis tas Mé di cas (In ter na ti o nal Com mi tee of Me di cal
Jour nal Edi tors), pu bli ca da na ín te gra ini ci al men te em N
Engl J Med 1991; 324: 424-28 e ac tu a li za da em Ou tu bro de
2008 e dis po ní vel em www.ICMJE.org. A po tí ti ca edi to rial
da Acta Reu ma to ló gi ca Por tu gue sa se gue as Re co men da -
ções de Po lí ti ca Edi to ri al (Edi to ri al Po licy Sta te ments) emi -
ti das pelo Con se lho de Edi to res Ci en tí fi cos (Coun cil of
Sci en ce Edi tors), dis po ní veis em www.coun cil sci en ce e di -
tors.org/ser vi ces/draft_ap pro ved.cfm.
A Re vis ta está in de xa da no Pub Med/Med li ne e os ar ti -
gos es tão dis po ní veis on li ne na ín te gra, com aces so aber -
to e gra tui to. 
Os ar ti gos de vem pre fe ren ci al men te ser re di gi dos em
in glês. Os ar ti gos em lín gua por tu gue sa tam bém po dem
ser sub me ti dos para apre cia ção. 
O ri gor e a exac ti dão dos con te ú dos, as sim como as
opi ni ões ex pres sas são da ex clu si va res pon sa bi li da de dos
au to res.
Os au to res de vem de cla rar po ten ci ais con fli tos de in -
te res se.
Os ar ti gos não po dem ter sido an te rior men te pu bli ca -
dos nou tra re vis ta. Quan do o ar ti go é acei te para pu bli ca -
ção é man da tó rio o en vio via e-mail de do cu men to di gi -
ta li za do, as si na do por to dos os au to res, com a trans fe rên -
cia dos di rei tos de au tor para a Acta Reu ma to ló gi ca Por -
tu gue sa.
Os ar ti gos pu bli ca dos fi ca rão pro pri e da de da re vis ta,
não po den do ser re pro du zi dos, no todo ou em par te, sem
au to ri za ção dos edi to res.
A acei ta ção dos ori gi nais en vi a dos para pu bli ca ção é
sem pre con di cio na da a ava lia ção pe los con sul to res edi -
to ri ais. Nes ta ava lia ção os ar ti gos po de rão ser:
a) acei tes sem al te ra ções;
b) acei tes após mo di fi ca ções pro pos tas pe los re vi so res;
c) re cu sa dos.
Em to dos os ca sos os pa re ce res dos con sul to res se rão
in te gral men te co mu ni ca dos aos au to res.
Quan do são pro pos tas al te ra ções, o au tor de ve rá en -
vi ar via e-mail no pra zo de 1 mês, uma car ta ao edi tor e a
cada um dos re vi so res res pon den do a to das as ques tões
co lo ca das e uma ver são re vis ta do ar ti go com as al te ra ções
in se ri das des ta ca das com cor di fe ren te.
Ins tru ções aos Au to res
To dos os ma nus cri tos que não es te jam em con for mi -
da de com as ins tru ções que se se guem po dem ser en vi a -
dos para mo di fi ca ções an tes de se rem re vis tos pe los con -
sul to res.
To dos os tra ba lhos de vem ser en vi a dos por e-mail para:
edtecnicarp@gmail.com. 
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Não in di car o nú me ro da re vis ta nem o mês da pu bli -
ca ção.
Seguem-se alguns exemplos de como devem constar
os vários tipos de referências:
– Re vis ta
Ape li do e ini ci ais do(s) au tor(es). Tí tu lo do ar ti go.
Nome da re vis ta Ano; Vo lu me: Pá gi nas.
Ex.: Hill J, Bird HA, Hopkins R, Lawton C, Wright V. Sur -
vey of sa tis fac ti on with care in a rheu ma to logy out pa -
tient cli nic. Ann Rheum Dis 1992; 51:195-197.
– Ar ti go pu bli ca do on li ne (in se rir DOI )
Ex.: Pe ter A Merkel, Da vid Curthbertson, Ber nhard
Hellmich et al. Com pa ri son of di se a se ac ti vity me a su res
for ANCA-as so cia ted vas cu li tis. Ann Rheum Dis Pu blis hed
On li ne First: 29 July 2008. doi:10.1136/ard.2008. 097758 
– Ca pí tu lo de li vro
Nome(s) e ini ci ais do(s) au tor(es) do ca pí tu lo. Tí tu lo
do ca pí tu lo. In: Nome(s) e ini ci ais do(s) edi tor(es) mé di -
co(s). Tí tu lo do li vro. Ci da de: Nome da casa edi to ra, ano
de pu bli ca ção: pri mei ra a úl ti ma pá gi na do ca pí tu lo.
Ex.: Stewart AF. Hyper cal ce mia re sul ting from me di ca -
ti ons. In: Fa vus MJ, ed. Pri mer on the Me ta bo lic Bone Di -
se a ses and Di sor der of Mi ne ral Me ta bo lism. New York:
Ra ven Press, 1993: 177-178.
– Li vro
Nome(s) e ini ci ais do(s) au tor(es). Tí tu lo do li vro. Ci -
da de: Nome da casa edi to ra, ano de pu bli ca ção: pá gi na(s).
Ex.: Lo rig K. Pa ti ent Edu ca ti on. A prac ti cal ap pro ach.
St. Lou is: Mosby-Year Book;1992: 51.
– Do cu men to elec tró ni co
Ex: Pro gra ma Na ci o nal de Luta Con tra a Tu ber cu lo se.
Sis te ma de Vi gi lân cia (SVIG-TB). Di rec ção-Ge ral da Saú -
de - Di vi são de Doen ças Trans mis sí veis, Mar ço de 2005
http://www.dgsau de.pt/uplo ad/mem bro.id/ fi chei ros/
i006875.pdf. Ace di do em 25 Ja nei ro de 2008
As re fe rên cias a tra ba lhos ain da não pu bli ca dos, co -
mu ni ca ções em re u ni ões, não pu bli ca das em li vros de
re su mos, ou co mu ni ca ções pes so ais de vem ser ci ta das no
tex to e não como re fe rên cias for mais.
A exac ti dão e o ri gor das re fe rên cias são da res pon sa -
bi li da de do au tor.
Ta be las: As ta be las a in se rir de vem ser as si na la das no
tex to em nu me ra ção ro ma na e cum prir o li mi te des cri to
aci ma. Cada ta be la de ve rá ser apre sen ta da em fo lha se -
pa ra da, dac ti lo gra fa da a 2 es pa ços. Na par te su pe rior de -
vem apre sen tar um tí tu lo su cin to mas in for ma ti vo, de
modo a po der ser com pre en di do sem re cur so ao tex to. Na
par te in fe rior da ta be la deve cons tar a ex pli ca ção das
abre vi a tu ras uti li za das. Nas ta be las de vem ser evi ta dos os
tra ços ver ti cais e os tra ços ho ri zon tais, es tes de vem ser -
vir ape nas como se pa ra do res de tí tu los e sub tí tu los.
Fi gu ras: As fi gu ras a in se rir de vem ser as si na la das no
tex to em nu me ra ção ára be e cum prir o li mi te de fi ni do
aci ma. As le gen das das fi gu ras de vem ser dac ti lo gra fa das
a dois es pa ços numa fo lha se pa ra da, de pois da bi bli o gra -
fia. As fi gu ras de vem ser en vi a das em su por te in for má ti -
co com fi chei ros se pa ra dos para cada fi gu ra, em for ma -
to JPEG ou TIFF.
Edi to ri ais: Os edi to ri ais se rão so li ci ta dos por con vi te
do Edi tor. Os edi to ri ais se rão co men tá rios so bre tó pi cos
 actuais ou so bre ar ti gos pu bli ca dos na re vis ta. O tex to dos
edi to ri ais não deve ex ce der as 1.200 pa la vras, um má ximo
de 15 re fe rên cias e não deve con ter qua dros ou fi gu ras.
Ar ti gos de re vi são:Es tes ar ti gos se rão pre fe ren ci al men -
te so li ci ta dos pelo Edi tor. No en tan to, os au to res in te res -
sa dos em apre sen tar um ar ti go de re vi são po dem con tac -
tar o Edi tor para dis cus são dos tó pi cos a apre sen tar.
O ar ti go de re vi são não deve ex ce der as 4.000 pa la -
vras, 6 ta be las/fi gu ras e 100 re fe rên cias. 
Car tas ao Edi tor: As car tas ao edi tor de vem cons ti tuir
um co men tá rio crí ti co a um ar ti go da re vis ta ou uma pe -
que na nota so bre um tema ou caso clí ni co. Não de vem
ex ce der as 600 pa la vras, uma fi gu ra ou um qua dro, e um
má xi mo de 10 re fe rên cias bi bli o grá fi cas.
Ima gens em reu ma to lo gia: Po dem ser sub me ti das
ima gens de par ti cu lar in te res se. As fi gu ras, no má xi mo de
4, de vem ser en vi a das em for ma to JPEG ou TIFF de boa
re so lu ção. O tex to acom pa nhan te não deve ul tra pas sar as
500 pa la vras.
Mo di fi ca ções e re vi sões: No caso da acei ta ção do ar -
ti go ser con di cio na da a mo di fi ca ções, es tas de ve rão ser
fei tas pe los au to res no pra zo de 1 mês.
Quan do são pro pos tas al te ra ções, o au tor de ve rá en -
de re çar uma car ta ao edi tor e a cada um dos re vi so res
res pon den do a to dos as ques tões co lo ca das. De ve rá ain -
da sub me ter uma ver são re vis ta do ar ti go com as al te -
ra ções in se ri das des ta ca das com cor di fe ren te.
As pro vas ti po grá fi cas se rão, sem pre que pos sí vel, en -
vi a das aos au to res con ten do a in di ca ção do pra zo para
re vi são con so an te as ne ces si da des edi to ri ais da re vis ta.
Mi nu ta da car ta de sub mis são a en vi ar ao Edi tor, di gi -
ta li za da, por e-mail:
Enviar este documento com o manuscrito para:
edtecnicarp@gmail.com
Edi tor
Acta Reu ma to ló gi ca Por tu gue sa
O(s) au tor(es) cer ti fi ca(m) que o ma nus cri to in ti tu la -
do: ____________________________________________
(ref. ARP_________) é ori gi nal, que to das as afir ma ções
apre sen ta das como fac tos são ba sea dos na in ves ti ga -
ção do(s) au tor(es), que o ma nus cri to, quer em par te
quer no todo, não in frin ge ne nhum copyright e não
vio la ne nhum di rei to da pri va ci da de, que não foi pu -
bli ca do em par te ou no todo e que não foi sub me ti do
para pu bli ca ção, no todo ou em par te, nou tra re vis ta,
e que os au to res têm o di rei to ao copyright.
To dos os au to res de cla ram ain da que par ti ci pa ram no
tra ba lho, se res pon sa bi li zam por ele e que não exis te,
da par te de qual quer dos au to res con fli to de in te res -
ses nas afir ma ções pro fe ri das no tra ba lho.
Os au to res, ao sub me te rem o tra ba lho para pu bli ca -
ção, trans fe rem para a Acta Reu ma to ló gi ca Por tu guesa
to dos os di rei tos a in te res ses do copyright do ar ti go.
Todos os autores devem assinar
Data: __________________________________________
Nome (maiúsculas): ____________________________
Assinatura: ____________________________________
